Lu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lu Chen has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Danfeng Xu
3 shared publications- Ada Tsui-Lin Ng
Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong, China (Hong Kong)
2 shared publications - Chi Yao
Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China (Hong Kong)
2 shared publications - Cho Wing Bryan Li
Centre of Cancer Medicine, The University of Hong Kong, Hong Kong SAR, China
2 shared publications - Da Huang
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Danfeng Xu
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
METTL3-mediated m6A modification stabilizes YOD1 to promote Bcl-xL-dependent enzalutamide resistance in prostate cancer
- 16 November 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
Open AccessMETTL3-mediated m6A modification stabilizes YOD1 to promote Bcl-xL-dependent enzalutamide resistance in prostate cancer
- Open Access
- 14 August 2026
- Published by Elsevier in Redox Biology
- Vol. 96
P4HA3-mediated hydroxylation of SLC7A11 drives tyrosine kinase inhibitor resistance by suppressing ferroptosis in clear cell renal cell carcinoma
- 14 August 2026
- Published by Elsevier in Redox Biology
- Vol. 96
Open AccessP4HA3-mediated hydroxylation of SLC7A11 drives tyrosine kinase inhibitor resistance by suppressing ferroptosis in clear cell renal cell carcinoma
- 1 July 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (7)
Peri-Arterial Neural Dissection During Adrenal Surgery Provides a Denervation-Like Benefit in Hypertension Control
BACKGROUND: Peri-arterial neural tissue surrounding the renal artery contributes to sympathetic overactivity in hypertension. During adrenal surgery, surgical peri-arterial neural dissection may interrupt these fibers and exert a renal denervation-like effect. Whether this maneuver improves postoperative blood pressure control remains unclear. METHODS: We retrospectively reviewed 127 hypertensive patients who underwent adrenal surgery between January 2022 and March 2025. According to intraoperative findings, patients were classified into a surgical peri-arterial neural dissection group or a nondissection group. After 1:2 manual matching by age, sex, and hypertension duration, 54 patients were included. Postoperative hypertension remission and changes in antihypertensive medication use, quantified by the defined daily dose, were assessed. Multivariable logistic regression was used to explore factors associated with postoperative nonremission. Renal and adrenal function markers were compared between groups. RESULTS: The surgical peri-arterial neural dissection group had a higher remission rate than the nondissection group (50.0% versus 16.1%; P =0.008). Surgical peri-arterial neural dissection was independently associated with lower odds of postoperative nonremission (odds ratio, 0.150 [95% CI, 0.030–0.744]; P =0.020), supporting its potential role in improving postoperative blood pressure control. Patients in the dissection group showed greater reductions in antihypertensive medication use (median change in defined daily dose, −1.0 versus 0.0; P =0.006). Creatinine, blood urea nitrogen, cortisol, and adrenocorticotropic hormone levels were similar between groups. CONCLUSIONS: Surgical peri-arterial neural dissection performed during adrenal surgery was associated with improved postoperative blood pressure control and reduced medication burden without evidence of impaired renal or adrenal function.
- 1 July 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (7)
Peri-Arterial Neural Dissection During Adrenal Surgery Provides a Denervation-Like Benefit in Hypertension Control
BACKGROUND: Peri-arterial neural tissue surrounding the renal artery contributes to sympathetic overactivity in hypertension. During adrenal surgery, surgical peri-arterial neural dissection may interrupt these fibers and exert a renal denervation-like effect. Whether this maneuver improves postoperative blood pressure control remains unclear. METHODS: We retrospectively reviewed 127 hypertensive patients who underwent adrenal surgery between January 2022 and March 2025. According to intraoperative findings, patients were classified into a surgical peri-arterial neural dissection group or a nondissection group. After 1:2 manual matching by age, sex, and hypertension duration, 54 patients were included. Postoperative hypertension remission and changes in antihypertensive medication use, quantified by the defined daily dose, were assessed. Multivariable logistic regression was used to explore factors associated with postoperative nonremission. Renal and adrenal function markers were compared between groups. RESULTS: The surgical peri-arterial neural dissection group had a higher remission rate than the nondissection group (50.0% versus 16.1%; P =0.008). Surgical peri-arterial neural dissection was independently associated with lower odds of postoperative nonremission (odds ratio, 0.150 [95% CI, 0.030–0.744]; P =0.020), supporting its potential role in improving postoperative blood pressure control. Patients in the dissection group showed greater reductions in antihypertensive medication use (median change in defined daily dose, −1.0 versus 0.0; P =0.006). Creatinine, blood urea nitrogen, cortisol, and adrenocorticotropic hormone levels were similar between groups. CONCLUSIONS: Surgical peri-arterial neural dissection performed during adrenal surgery was associated with improved postoperative blood pressure control and reduced medication burden without evidence of impaired renal or adrenal function.
- Open Access
- 26 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e72597
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial
Background: Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). Objective: We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. Methods: We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. Results: This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. Conclusions: Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. Trial Registration: ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 International Registered Report Identifier (IRRID): DERR1-10.2196/72597
- 26 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e72597
Open AccessSurveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial
Background: Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). Objective: We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. Methods: We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. Results: This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. Conclusions: Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. Trial Registration: ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 International Registered Report Identifier (IRRID): DERR1-10.2196/72597
- Open Access
- 13 February 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial (Preprint)
BACKGROUND Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). OBJECTIVE We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. METHODS We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. RESULTS This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. CONCLUSIONS Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. CLINICALTRIAL ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/72597
- 13 February 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessSurveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial (Preprint)
BACKGROUND Urothelial carcinoma is one of the most commonly diagnosed cancers worldwide, with a poor 5-year survival rate. As genomics is the backbone of the precision medicine paradigm, the genetic signature in circulating tumor DNA (ctDNA) is emerging as a pivotal biomarker for detecting early-stage cancer and molecular residual disease (MRD). OBJECTIVE We aim to evaluate the feasibility and preliminary effects of a ctDNA-based sequencing approach for detecting MRD and guiding adjuvant chemotherapy in postoperative urothelial carcinomas. METHODS We will perform a stratified 2-arm pilot randomized controlled trial in 2 tertiary hospitals in Hong Kong, involving patients with urothelial carcinomas (pT2-4a N0-2 M0) undergoing radical resection. We plan to recruit 20 patients and determine stratification according to their MRD status before randomization. Patients in each stratum (MRD-positive and MRD-negative groups) will be randomly allocated to either a 4-cycle gemcitabine plus cisplatin chemotherapy arm or a standard management arm in a 1:1 ratio. ctDNA MRD will be tested using a personalized next-generation sequencing panel, which is designed based on the individual’s whole exome sequencing results from the operation specimen. The primary outcome is the feasibility of this trial (ie, recruitment, retention, adherence, and completeness). The secondary outcome is treatment-related adverse events. Exploratory outcomes include radiographic disease-free survival, cancer-specific survival, overall survival, ctDNA clearance in patients with ctDNA MRD-positive status, quality of life, fear of cancer recurrence, and cost-effectiveness. Benchmarks for feasibility evaluation are set as (1) ≥20% recruitment response rate, (2) ≤20% loss to follow-up or withdrawal, (3) ≥80% intervention adherence, and (4) ≤20% missing value rate. Each benchmark will be assigned one score, and a total score of 4, 2 to 3, and 0 to 1 will be deemed high, medium, and low feasibility, respectively. Safety evaluations will be presented as numbers and proportions of the adverse events. ANOVA and the Kruskal-Wallis test will be used for continuous outcome variables, whereas the chi-square test and the Fisher exact test will be used for categorical outcome variables. Hazard ratios will be calculated to compare the preliminary treatment effect of the gemcitabine plus cisplatin arm against the standard management arm on survival within each MRD group. RESULTS This project was funded in February 2024. Patient recruitment started on May 2, 2024. Recruitment and data collection for the trial are ongoing. Data analysis will be performed in mid-2025 and the results of this study are expected to be published in late 2025. CONCLUSIONS Genetic signature in ctDNA is informative for personalized management of postoperative urothelial carcinomas, including personalized treatment and early detection of disease progression. CLINICALTRIAL ClinicalTrials.gov NCT06257017; https://clinicaltrials.gov/study/NCT06257017 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/72597
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2433
A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Background. Despite advances in therapy, treatment of R/R NHL remains a challenge. PEVO (TAK924) is a first-in-class, selective, small molecule, NAE inhibitor with preclinical activity in NHL, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and diffuse large B cell lymphoma (DLBCL). We and others have demonstrated synergy between PEVO and the Bruton tyrosine kinase inhibitor ibrutinib, in in vitro and in vivo models of CLL and MCL. We report the results of a phase 1 study of PEVO in combination with ibrutinib in patients with R/R NHL. Methods. This was a multicenter, open-label, Phase I, investigator-sponsored study (NCT03479268). Patients with NHL or CLL ≥18 years of age whose disease had relapsed or was refractory to ≥1 prior lines of therapy were enrolled. The Phase I portion of the study followed mTPI design with five planned dose levels of PEVO (15, 20, 25, 37.5 and 50 mg/m 2). PEVO was given IV on days 1, 3 and 5 of a 21-day cycle for a total of 8 cycles. Ibrutinib was administered once a day starting on Cycle 1 day 2 at a fixed dose of 420 mg (560 mg in MCL) orally for a total of 18 cycles. Primary study objectives were safety and tolerability; secondary objectives included preliminary measures of efficacy. Response was assessed by Lugano (NHL) and IWCLL criteria. Exploratory objectives included pharmacokinetic (PK) and pharmacodynamic endpoints. Dose limiting toxicities (DLT) were defined as grade 4 hematologic or grade 3 non-hematologic toxicities. Results. Of the eighteen patients enrolled, 8 had MCL, 4 had DLBCL, 4 had CLL and one patient each had marginal zone and follicular lymphoma; 72% (13/18) were men. Median age was 71 (51-90) years, 94% had an ECOG performance status ≤1. Patients had received a median of 1 prior line of therapy (range, 1-3), 3 patients had undergone prior autologous stem cell transplant. Three patients each were treated on dose level cohorts 1-4. One DLT, mediastinal hemorrhage, was observed at dose level 5. Therefore, the recommended phase 2 dose (RP2D) of PEVO was 50 mg/m 2. The most common treatment-related adverse events (AEs, any grade) were bruising and diarrhea (44% each; Table 1). There was one case each (5.6%) of the following grade 3-4 AEs: arthralgia, bone pain, diarrhea and mediastinal hemorrhage. Three patients (16.6%) developed grade 1-2 atrial fibrillation on study but all continued therapy. Treatment discontinuation due to AE occurred in one patient (5.6%, mediastinal hemorrhage). The overall response rate (ORR) was 66% for all patients. Among eight patients with MCL, ORR was 100% (50% complete response). The median PEVO elimination T 1/2 was 6.7 h (range, 4.9-12.1 h) on day 1 and 6.4 h (3.2-11.0 h) on day 3 (Wilcoxon p=0.12). PEVO exhibited linear PK with dose-dependent increases in C max and AUC (0-inf) (Figure 1), which were unaffected by concurrent ibrutinib (Wilcoxon p=0.09 and 0.94, respectively). Discussion. The combination of pevonedistat and ibrutinib is safe and well-tolerated in patients with R/R NHL. It is associated with high response rates in patients with R/R MCL. The study is currently enrolling patients in the expansion cohort to further characterize the efficacy of this promising regimen.
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2433
Open AccessA Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Background. Despite advances in therapy, treatment of R/R NHL remains a challenge. PEVO (TAK924) is a first-in-class, selective, small molecule, NAE inhibitor with preclinical activity in NHL, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and diffuse large B cell lymphoma (DLBCL). We and others have demonstrated synergy between PEVO and the Bruton tyrosine kinase inhibitor ibrutinib, in in vitro and in vivo models of CLL and MCL. We report the results of a phase 1 study of PEVO in combination with ibrutinib in patients with R/R NHL. Methods. This was a multicenter, open-label, Phase I, investigator-sponsored study (NCT03479268). Patients with NHL or CLL ≥18 years of age whose disease had relapsed or was refractory to ≥1 prior lines of therapy were enrolled. The Phase I portion of the study followed mTPI design with five planned dose levels of PEVO (15, 20, 25, 37.5 and 50 mg/m 2). PEVO was given IV on days 1, 3 and 5 of a 21-day cycle for a total of 8 cycles. Ibrutinib was administered once a day starting on Cycle 1 day 2 at a fixed dose of 420 mg (560 mg in MCL) orally for a total of 18 cycles. Primary study objectives were safety and tolerability; secondary objectives included preliminary measures of efficacy. Response was assessed by Lugano (NHL) and IWCLL criteria. Exploratory objectives included pharmacokinetic (PK) and pharmacodynamic endpoints. Dose limiting toxicities (DLT) were defined as grade 4 hematologic or grade 3 non-hematologic toxicities. Results. Of the eighteen patients enrolled, 8 had MCL, 4 had DLBCL, 4 had CLL and one patient each had marginal zone and follicular lymphoma; 72% (13/18) were men. Median age was 71 (51-90) years, 94% had an ECOG performance status ≤1. Patients had received a median of 1 prior line of therapy (range, 1-3), 3 patients had undergone prior autologous stem cell transplant. Three patients each were treated on dose level cohorts 1-4. One DLT, mediastinal hemorrhage, was observed at dose level 5. Therefore, the recommended phase 2 dose (RP2D) of PEVO was 50 mg/m 2. The most common treatment-related adverse events (AEs, any grade) were bruising and diarrhea (44% each; Table 1). There was one case each (5.6%) of the following grade 3-4 AEs: arthralgia, bone pain, diarrhea and mediastinal hemorrhage. Three patients (16.6%) developed grade 1-2 atrial fibrillation on study but all continued therapy. Treatment discontinuation due to AE occurred in one patient (5.6%, mediastinal hemorrhage). The overall response rate (ORR) was 66% for all patients. Among eight patients with MCL, ORR was 100% (50% complete response). The median PEVO elimination T 1/2 was 6.7 h (range, 4.9-12.1 h) on day 1 and 6.4 h (3.2-11.0 h) on day 3 (Wilcoxon p=0.12). PEVO exhibited linear PK with dose-dependent increases in C max and AUC (0-inf) (Figure 1), which were unaffected by concurrent ibrutinib (Wilcoxon p=0.09 and 0.94, respectively). Discussion. The combination of pevonedistat and ibrutinib is safe and well-tolerated in patients with R/R NHL. It is associated with high response rates in patients with R/R MCL. The study is currently enrolling patients in the expansion cohort to further characterize the efficacy of this promising regimen.
- Open Access
- 17 June 2021
- Published by Springer Nature in npj Genomic Medicine
- Vol. 6 (1) , 1-11
Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes
The emerging field of long noncoding RNA (lncRNA)-immunity has provided a new perspective on cancer immunity and immunotherapies. The lncRNA modifiers of infiltrating immune cells in the tumor immune microenvironment (TIME) and their impact on tumor behavior and disease prognosis remain largely uncharacterized. In the present study, a systems immunology framework integrating the noncoding transcriptome and immunogenomics profiles of 9549 tumor samples across 30 solid cancer types was used, and 36 lncRNAs were identified as modifier candidates underlying immune cell infiltration in the TIME at the pan-cancer level. These TIME lncRNA modifiers (TIL-lncRNAs) were able to subclassify various tumors into three de novo pan-cancer subtypes characterized by distinct immunological features, biological behaviors, and disease prognoses. Finally, a TIL-lncRNA-derived immune state index (TISI) that was reflective of immunological and oncogenic states but also predictive of patients’ prognosis was proposed. Furthermore, the TISI provided additional prognostic value for existing tumor immunological and molecular subtypes. By applying the TISI to tumors from different clinical immunotherapy cohorts, the TISI was found to be significantly negatively correlated with immune-checkpoint genes and to have the ability to predict the effectiveness of immunotherapy. In conclusion, the present study provided comprehensive resources and insights for future functional and mechanistic studies on lncRNA-mediated cancer immunity and highlighted the potential of the clinical application of lncRNA-based immunotherapeutic strategies in precision immunotherapy.
- 17 June 2021
- Published by Springer Nature in npj Genomic Medicine
- Vol. 6 (1) , 1-11
Open AccessPan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes
The emerging field of long noncoding RNA (lncRNA)-immunity has provided a new perspective on cancer immunity and immunotherapies. The lncRNA modifiers of infiltrating immune cells in the tumor immune microenvironment (TIME) and their impact on tumor behavior and disease prognosis remain largely uncharacterized. In the present study, a systems immunology framework integrating the noncoding transcriptome and immunogenomics profiles of 9549 tumor samples across 30 solid cancer types was used, and 36 lncRNAs were identified as modifier candidates underlying immune cell infiltration in the TIME at the pan-cancer level. These TIME lncRNA modifiers (TIL-lncRNAs) were able to subclassify various tumors into three de novo pan-cancer subtypes characterized by distinct immunological features, biological behaviors, and disease prognoses. Finally, a TIL-lncRNA-derived immune state index (TISI) that was reflective of immunological and oncogenic states but also predictive of patients’ prognosis was proposed. Furthermore, the TISI provided additional prognostic value for existing tumor immunological and molecular subtypes. By applying the TISI to tumors from different clinical immunotherapy cohorts, the TISI was found to be significantly negatively correlated with immune-checkpoint genes and to have the ability to predict the effectiveness of immunotherapy. In conclusion, the present study provided comprehensive resources and insights for future functional and mechanistic studies on lncRNA-mediated cancer immunity and highlighted the potential of the clinical application of lncRNA-based immunotherapeutic strategies in precision immunotherapy.
- 14 June 2017
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 43 (9) , 1472-1480
Integrated gene expression profiling and chromatin immunoprecipitation followed by sequencing: Analysis of the C‐terminal binding protein in breast cancer
Aim: This study explored the possible mechanisms of the transcriptional regulatory activities of C‐terminal binding protein (CtBP) and the role of CtBP in the pathogenesis of breast cancer.Methods: Microarray data of GSE36529, including three CtBP‐knockdown breast cancer MCF‐7 cell samples, three control knockdown samples and data of CtBP binding profile in MCF‐7 cells, was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened between CtBP‐knockdown MCF‐7 cell samples and controls. Newly developed chromatin immunoprecipitation followed by sequencing technology was used to identify the CtBP binding regions. The direct target genes of CtBP were identified using ChIP‐Array software and a regulatory network was constructed, followed by gene ontology (GO) enrichment analysis of all identified DEGs and DEGs targeted by CtBP.Results: In total, 404 DEGs were identified in CtBP‐knockdown MCF‐7 cell samples. These DEGs were enriched in different GO terms, such as cellular response to stress and cell cycle, endoplasmic reticulum and nucleotide binding. Additionally, 143 DEGs were identified as potential direct targets of CtBP in the regulatory network. CtBP target genes such as hypoxia up‐regulated 1, BTG family member 2 and endothelin 1 were mainly related to response to hypoxia and regulation of cell proliferation.Conclusions: Hypoxia up‐regulated 1, BTG family member 2 and endothelin 1 may be associated with the progression of breast cancer through interaction with CtBP in different biological processes. CtBP may be a therapeutic target for the treatment of breast cancer.
- 14 June 2017
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 43 (9) , 1472-1480
Integrated gene expression profiling and chromatin immunoprecipitation followed by sequencing: Analysis of the C‐terminal binding protein in breast cancer
Aim: This study explored the possible mechanisms of the transcriptional regulatory activities of C‐terminal binding protein (CtBP) and the role of CtBP in the pathogenesis of breast cancer.Methods: Microarray data of GSE36529, including three CtBP‐knockdown breast cancer MCF‐7 cell samples, three control knockdown samples and data of CtBP binding profile in MCF‐7 cells, was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened between CtBP‐knockdown MCF‐7 cell samples and controls. Newly developed chromatin immunoprecipitation followed by sequencing technology was used to identify the CtBP binding regions. The direct target genes of CtBP were identified using ChIP‐Array software and a regulatory network was constructed, followed by gene ontology (GO) enrichment analysis of all identified DEGs and DEGs targeted by CtBP.Results: In total, 404 DEGs were identified in CtBP‐knockdown MCF‐7 cell samples. These DEGs were enriched in different GO terms, such as cellular response to stress and cell cycle, endoplasmic reticulum and nucleotide binding. Additionally, 143 DEGs were identified as potential direct targets of CtBP in the regulatory network. CtBP target genes such as hypoxia up‐regulated 1, BTG family member 2 and endothelin 1 were mainly related to response to hypoxia and regulation of cell proliferation.Conclusions: Hypoxia up‐regulated 1, BTG family member 2 and endothelin 1 may be associated with the progression of breast cancer through interaction with CtBP in different biological processes. CtBP may be a therapeutic target for the treatment of breast cancer.